Prostate:抑制STAT3可防止体内前列腺癌的骨转移

2021-04-21 AlexYang MedSci原创

前列腺癌(PC)转移到骨骼会形成以硬化为主的病变,目前对骨转移性疾病还没有治愈的办法。转录因子信号转导和转录激活因子3(STAT3)认为是转移的驱动因素,但它作为骨转移的治疗靶点的潜力还没有研究。

前列腺癌(PC)转移到骨骼会形成以硬化为主的病变,目前对骨转移性疾病还没有治愈的办法。转录因子信号转导和转录激活因子3(STAT3)认为是转移的驱动因素,但它作为骨转移的治疗靶点的潜力还没有研究。

最近,有研究人员首次评估了STAT3抑制剂Napabucasin作为骨转移性PC治疗方案的情况

研究结果发现,小分子STAT3抑制剂Stattic和Napabucasin都有效地削弱了PC细胞在体外的转移能力。此外,用Napabucasin治疗可以防止体内胫骨转移形成,也可以防止媒介处理VCaP异种移植中观察到的肿瘤引起的硬化骨反应。另外,用Napabucasin治疗已形成的骨CRPC,与媒介处理的动物相比,肿瘤负担和肿瘤引起的骨小梁体积都明显下降。与媒介处理的异种移植物相比,Napabucasin治疗的异种移植物的Ki67染色减少,证实了其抗有丝分裂的作用。基因表达量分析显示,股骨骨髓(BM)生态位的基因表达发生了变化,以维护造血干细胞和髓系。更多的是,Napabucasin处理的小鼠BM中红细胞数量的大幅增加。此外,在使用几种不同PC细胞系的骨异种移植模型中,免疫组化显示了肿瘤细胞周围的成骨细胞/骨膜细胞中STAT3磷酸化具有独特的模式。

靶向STAT3可防止前列腺癌细胞的骨转移和减弱成骨细胞响应

最后,研究人员指出,抑制STAT3的活性会破坏骨转移的生态位,并同时靶向小鼠PC的骨骼建立和晚期骨转移CRPC,表明STAT3是骨骼转移性疾病的分子靶向治疗候选靶标

原始出处:

Malin Hagberg Thulin, Jorma Määttä, Anna Linder et al. Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo. Prostate. Apr 2021

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1348979, encodeId=cc4413489e95b, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Fri Apr 23 05:47:21 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364721, encodeId=5f651364e21b0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Apr 23 05:47:21 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602359, encodeId=5b2b1602359ee, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Apr 23 05:47:21 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040999, encodeId=20ec104099979, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 21 17:47:21 CST 2021, time=2021-04-21, status=1, ipAttribution=)]
    2021-04-23 李研东
  2. [GetPortalCommentsPageByObjectIdResponse(id=1348979, encodeId=cc4413489e95b, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Fri Apr 23 05:47:21 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364721, encodeId=5f651364e21b0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Apr 23 05:47:21 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602359, encodeId=5b2b1602359ee, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Apr 23 05:47:21 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040999, encodeId=20ec104099979, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 21 17:47:21 CST 2021, time=2021-04-21, status=1, ipAttribution=)]
    2021-04-23 lsndxfj
  3. [GetPortalCommentsPageByObjectIdResponse(id=1348979, encodeId=cc4413489e95b, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Fri Apr 23 05:47:21 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364721, encodeId=5f651364e21b0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Apr 23 05:47:21 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602359, encodeId=5b2b1602359ee, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Apr 23 05:47:21 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040999, encodeId=20ec104099979, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 21 17:47:21 CST 2021, time=2021-04-21, status=1, ipAttribution=)]
    2021-04-23 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1348979, encodeId=cc4413489e95b, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Fri Apr 23 05:47:21 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364721, encodeId=5f651364e21b0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Apr 23 05:47:21 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602359, encodeId=5b2b1602359ee, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Apr 23 05:47:21 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040999, encodeId=20ec104099979, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 21 17:47:21 CST 2021, time=2021-04-21, status=1, ipAttribution=)]
    2021-04-21 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

BJU Int:游离/总前列腺特异性抗原(PSA)检测与前列腺癌死亡率之间的关联研究

最近,有研究人员探讨了基线前列腺特异性抗原(PSA)(包括游离/总PSA比值)与前列腺癌死亡长期(30年)风险之间是否存在长期关联。

JCO:基因检测对低风险前列腺癌治疗策略选择的影响

风险相对较低的前列腺癌(PCa)患者在立即治疗或主动监测(AS)+延期治疗之间往往面临艰难的选择,基因检测有助于治疗方案选择吗?

Eur Radiol:CTA对前列腺动脉栓塞术的价值

前列腺动脉栓塞术是一个技术上相对困难的手术。然而到目前为止,对影响PAE技术困难度因素的研究十分有限,且迄今为止大多数的相关研究均对患者变量使用主观测量。

Prostate Cancer P D:恩杂鲁胺或阿比特龙治疗转移去势抵抗性前列腺癌男性的生活质量

恩杂鲁胺与醋酸阿比特龙加泼尼松(AAP)对转移去势抵抗性前列腺癌(mCRPC)的疗效相似,但作用机制不同。

Prostate Cancer P D:心理干预对前列腺癌抑郁、焦虑和苦恼的效果

前列腺癌的发病率越来越高,而死亡率越来越低,这将导致幸存者人数越来越多,健康状况负担会越来越重,因此,需要关注他们的心理健康。

Br J Cancer:尿液中雌激素水平可作为前列腺癌发生发展的风险指标

前列腺癌(PCa)作为全球男性中第二常见的癌症,在2018年有120万以上的确诊病例,死亡人数超过350,000。